| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9394 | 2011 |
| PD-1 blockade induces responses by inhibiting adaptive immune resistance PC Tumeh, CL Harview, JH Yearley, IP Shintaku, EJM Taylor, L Robert, ... Nature 515 (7528), 568-571, 2014 | 7023 | 2014 |
| Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015 | 6480 | 2015 |
| Cancer immunotherapy using checkpoint blockade A Ribas, JD Wolchok Science 359 (6382), 1350-1355, 2018 | 5862 | 2018 |
| Primary, adaptive, and acquired resistance to cancer immunotherapy P Sharma, S Hu-Lieskovan, JA Wargo, A Ribas Cell 168 (4), 707-723, 2017 | 4904 | 2017 |
| Genetic basis for clinical response to CTLA-4 blockade in melanoma A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ... New England Journal of Medicine 371 (23), 2189-2199, 2014 | 4707 | 2014 |
| Inhibition of mutated, activated BRAF in metastatic melanoma KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ... New England Journal of Medicine 363 (9), 809-819, 2010 | 4363 | 2010 |
| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England Journal of Medicine 369 (2), 134-144, 2013 | 4300 | 2013 |
| Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ... Cell 165 (1), 35-44, 2016 | 3279 | 2016 |
| IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade M Ayers, J Lunceford, M Nebozhyn, E Murphy, A Loboda, DR Kaufman, ... The Journal of clinical investigation 127 (8), 2930-2940, 2017 | 3244 | 2017 |
| Mutations associated with acquired resistance to PD-1 blockade in melanoma JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ... New England Journal of Medicine 375 (9), 819-829, 2016 | 3179 | 2016 |
| Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015 | 3063 | 2015 |
| Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles ME Davis, JE Zuckerman, CHJ Choi, D Seligson, A Tolcher, CA Alabi, ... Nature 464 (7291), 1067-1070, 2010 | 3032 | 2010 |
| Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation R Nazarian, H Shi, QI Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ... Nature 468 (7326), 973-977, 2010 | 2670 | 2010 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2642 | 2012 |
| Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ... New England Journal of Medicine 371 (20), 1867-1876, 2014 | 2508 | 2014 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 2177 | 2014 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 2107 | 2014 |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ... Nature 467 (7315), 596-599, 2010 | 2102 | 2010 |
| Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy R Cristescu, R Mogg, M Ayers, A Albright, E Murphy, J Yearley, X Sher, ... Science 362 (6411), eaar3593, 2018 | 2044 | 2018 |